Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,876 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Diseases, Chronic Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

NCT02729038
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Exercise and Vascular Function in Chronic Kidney Disease

NCT02050035
View directory record Official record
Conditions
Chronic Renal Insufficiency
Interventions
Aerobic Exercise Training
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Explore Transplant @Home Within Kaiser Permanente Southern California

NCT03389932
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Patient-Guided
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 1:16 PM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

VasQ External Support for Arteriovenous Fistula

NCT03242343
View directory record Official record
Conditions
Arterio-Venous Fistula, ESRD, Steal Syndrome, Aneurysm, Renal Failure, Renal Disease, Diabetes Mellitus, Kidney Failure
Interventions
VasQ
Device
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Peoria, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Phase 1 Interventional

Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia

NCT01057108
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
FOSTRAP Chewing Gum, Placebo chewing gum
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT

NCT02778516
View directory record Official record
Conditions
ESRD
Interventions
Sodium Restriction
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 25, 2026, 1:16 PM EDT
Recruiting Phase 2 Interventional

Neurovascular Transduction During Exercise in Chronic Kidney Disease

NCT02947750
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo
Drug · Other · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 25, 2026, 1:16 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients

NCT00447408
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Standard hemodialysis dietary instruction, Behavioral counseling plus PDA-based self-monitoring of diet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2010 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

NCT05182840
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

Resveratrol and Vascular Function in CKD

NCT03597568
View directory record Official record
Conditions
Chronic Kidney Diseases, Endothelial Dysfunction
Interventions
Resveratrol, Placebo
Dietary Supplement · Other
Lead sponsor
Diana Jalal
Other
Eligibility
45 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

NCT04075916
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 25, 2026, 1:16 PM EDT
Terminated Not applicable Interventional Results available

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

NCT02503735
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Disease
Interventions
Sofosbuvir/Ledipasvir FDC
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Treatment for Periodontal Disease in Dialysis Patients

NCT00937976
View directory record Official record
Conditions
Periodontal Disease
Interventions
Periodontal Scaling and Root Planing
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

Exercise Trial in Chronic Kidney Disease

NCT01462097
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Aerobic exercise training, Health Education
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 25, 2026, 1:16 PM EDT
Completed Phase 2 Interventional

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

NCT00440648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Mobile, Alabama • Riverside, California • Greenwood Village, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 25, 2026, 1:16 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Jackson Heart Study of Cardiovascular Disease Among African Americans

NCT00005485
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Coronary Disease, Hypertension, Cerebrovascular Disorders
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
35 Years to 84 Years
Enrollment
5,306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 25, 2026, 1:16 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 25, 2026, 1:16 PM EDT
Withdrawn Not applicable Interventional

Effects of Intensified Sodium Management in Hemodialysis Patients

NCT01015313
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
intensive sodium management
Other
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 25, 2026, 1:16 PM EDT
Completed No phase listed Observational

Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease

NCT02739750
View directory record Official record
Conditions
Polycystic Kidney Diseases
Interventions
No intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 25, 2026, 1:16 PM EDT
Completed No phase listed Observational Results available

Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

NCT05734989
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
BP, HbA1c, PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
Diagnostic Test · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 25, 2026, 1:16 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 25, 2026, 1:16 PM EDT